Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Dec 06, 2005
IMPAX Receives Final FDA Approval for Generic Version of OxyContin in 10mg, 20mg and 40mg Strengths; Sixth Approval in 2005
Nov 07, 2005
IMPAX Signs Exclusive Supply and Distribution Agreement with DAVA Pharmaceuticals for Oxycodone Hydrochloride Extended Release Tablets
Oct 24, 2005
IMPAX Announces Shire's Lawsuit Related to Generic Version of Adderall XR
Sep 29, 2005
IMPAX Prevails in Alza's Lawsuit Related to Generic Version of Ditropan XL
Sep 14, 2005
IMPAX Receives Final Approval for Generic Version of Glucophage(R) XR
Sep 02, 2005
IMPAX Announces Alza's Lawsuit Related to Generic Version Of Concerta
Aug 05, 2005
IMPAX Receives Notice of Delisting from Nasdaq
Aug 03, 2005
IMPAX Provides Further Update of Progress in Filing 10-K and 10-Q and Estimates of Results
Jun 27, 2005
IMPAX Laboratories, Inc. Agrees to Sell $75 Million of 3.5% Senior Subordinated Convertible Debentures Due 2012; Proceeds to be Used to Repay 1.250% Convertible Senior Subordinated Debentures Due 2024
Jun 20, 2005
IMPAX to Increase Existing Credit Facility
May 23, 2005
IMPAX Receives Notice of Additional Delinquency for Failure to File Form 10-Q
May 04, 2005
IMPAX Provides Updates on Progress to File 10-K and Related Matters
May 02, 2005
IMPAX Receives FDA Approval for Generic Version of Rimadyl, a Veterinary Product; Fourth Approval in 2005
Apr 18, 2005
IMPAX Receives Final FDA Approval for Generic Version Of Agrylin; Third Approval in 2005
Apr 06, 2005
IMPAX Receives Notice of Possible Delisting for Failure to File Form 10-K
Apr 01, 2005
IMPAX Names Arthur A. Koch, Jr. Senior Vice President, Finance, and Chief Financial Officer
Mar 31, 2005
IMPAX Announces Delay in 10-K Filing
Mar 24, 2005
IMPAX to Present at the Smith Barney Citigroup 2005 Healthcare Conference
Mar 14, 2005
IMPAX to File 2004 10-K Filing Extension
Mar 09, 2005
IMPAX Announces Biovail's Lawsuit Related to Generic Versions of Wellbutrin XL
Mar 04, 2005
IMPAX to Present at the Raymond James Institutional Investor Conference
Mar 03, 2005
IMPAX Launches Generic Version of OxyContin Controlled Release 80 mg Tablets
Mar 02, 2005
IMPAX Receives Final FDA Approval for Generic Version of Dantrium; Global Division to Launch Immediately
Feb 28, 2005
IMPAX Files Motion to Intervene as Defendant in Litigation Related to Generic Allegra-D
Feb 04, 2005
IMPAX to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Feb 02, 2005
IMPAX Receives Tentative FDA Approval for Generic Version of Ditropan XL; First Approval in 2005
Jan 05, 2005
IMPAX to Present at the JP Morgan Healthcare Conference

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top